Sunday, July 12, 2009

Thomas Stossel's Golden ACRE


A Harvard professor of medicine is organizing a pro-Big Pharma army.

Thomas Stossel, the American Cancer Society Professor of Medicine at Harvard Medical School, is spearheading a new nonprofit professional organization that is, according to Stossel’s preliminary description, “to be a forum for what we believe is a hitherto silent majority of individuals engaged in clinical service, medical education and medical innovation ready to oppose a small but well organized and well-funded coterie responsible for an anti-industry movement.”

The Association of Clinical Researchers and Educators (ACRE), slated to hold its charter conference this month, will be led by a steering committee consisting of physicians from Harvard Medical School, the State University of New York Downstate and the Mayo Clinic; it will be logistically managed by Rockpointe, a science-based medical communications company that produces educational programs for doctors that are often sponsored by pharmaceutical companies. So far, funding for ACRE has been covered completely out of pocket, though Stossel said he welcomes industry participation and support. The tentative schedule for July’s meeting includes more than two dozen speakers – doctors, industry representatives, health and patient association officials -- and topics range from policy explanation to the value of collaboration between medicine and industry (for which, of course, Stossel makes no apologies).

According to Stossel, the perceived risks of physician-industry relationships are too often demonized instead of assessed for value. “The damages are imaginary or speculative,” he said, adding that in the “crescendo” of anti-business sentiment in science and medicine, “no one wants to sign up to be abused by The New York Times or Senator Grassley.”


Insider's view: Who's backing this? Who's paying Rockpointe's bills?

Also - it's good to see they dont try and defend Biederman and Nemeroff - LOL


A note appended to an article by Stossel published in the British Medical Journal in early 2008 stated that he "is on the boards of directors and owns stock options in ZymeQuest and Critical Biologics Corporations, and his employer has licensed intellectual property to these companies, which may result in his receiving milestone payments, royalties and in the stock options having financial value. He receives fees for speaking to corporations and other organisations on the topic of conflict of interest. He has served on scientific advisory boards for Biogen, Dyax, and Merck."

4 comments:

Pharma Giles said...

Hey Jack, now we're "a well-funded coterie" Don't know about you, but the only funds I get are from the day job.

Are coteries like meerkats?

Of course, Stossel's "slate the messenger" group won't be well-funded at all...

Dan said...

Thanks to the Bayh Dole Act of the year 1980 in the United States, academic researchers have been metamorphosized into shrewd capitalists by the pharma industry.

Anti-pharma? Pharma has atrophied the scientific method, and liquified the asepsis at the apex of the authenticity of scientfic progress.

Anonymous said...

Dr. Stossel and his crowd, such Thomas Sullivan of Rockpointe Corporation, deserve their very own sourcewatch page

http://www.sourcewatch.org/index.php?title=Association_of_Clinical_Researchers_and_Educators

Anonymous said...

here's another take on Thomas Stossel

http://pogoblog.typepad.com/pogo/2011/07/the-association-of-clinical-researchers-and-educators-a-cult-narrative-for-the-grumpy-old-men-of-med.html